

FDA expands authorized use of REGEN-COV (casirivimab and imdevimab)

Dear Investor,

Please find attached a press release from our partner Regeneron:

<https://investor.regeneron.com/news-releases/news-release-details/fda-expands-authorized-use-regen-covtm-casirivimab-and-imdevimab>

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: karl.mahler@roche.com

Jon Kaspar Bayard

Phone: +41 61 68-83894

e-mail: jon_kaspar.bayard@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com